Cargando…
Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge
We describe the epidemiology, clinical features, and molecular characterization of enterohemorrhagic Escherichia coli (EHEC) infections caused by the singular hybrid pathotype O80:H2, and we examine the influence of antibiotics on Shiga toxin production. In France, during 2005–2014, a total of 54 pa...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994344/ https://www.ncbi.nlm.nih.gov/pubmed/27533474 http://dx.doi.org/10.3201/eid2209.160304 |
_version_ | 1782449311194284032 |
---|---|
author | Soysal, Nurcan Mariani-Kurkdjian, Patricia Smail, Yasmine Liguori, Sandrine Gouali, Malika Loukiadis, Estelle Fach, Patrick Bruyand, Mathias Blanco, Jorge Bidet, Philippe Bonacorsi, Stéphane |
author_facet | Soysal, Nurcan Mariani-Kurkdjian, Patricia Smail, Yasmine Liguori, Sandrine Gouali, Malika Loukiadis, Estelle Fach, Patrick Bruyand, Mathias Blanco, Jorge Bidet, Philippe Bonacorsi, Stéphane |
author_sort | Soysal, Nurcan |
collection | PubMed |
description | We describe the epidemiology, clinical features, and molecular characterization of enterohemorrhagic Escherichia coli (EHEC) infections caused by the singular hybrid pathotype O80:H2, and we examine the influence of antibiotics on Shiga toxin production. In France, during 2005–2014, a total of 54 patients were infected with EHEC O80:H2; 91% had hemolytic uremic syndrome. Two patients had invasive infections, and 2 died. All strains carried stx2 (variants stx2a, 2c, or 2d); the rare intimin gene (eae-ξ); and at least 4 genes characteristic of pS88, a plasmid associated with extraintestinal virulence. Similar strains were found in Spain. All isolates belonged to the same clonal group. At subinhibitory concentrations, azithromycin decreased Shiga toxin production significantly, ciprofloxacin increased it substantially, and ceftriaxone had no major effect. Antibiotic combinations that included azithromycin also were tested. EHEC O80:H2, which can induce hemolytic uremic syndrome complicated by bacteremia, is emerging in France. However, azithromycin might effectively combat these infections. |
format | Online Article Text |
id | pubmed-4994344 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-49943442016-09-08 Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge Soysal, Nurcan Mariani-Kurkdjian, Patricia Smail, Yasmine Liguori, Sandrine Gouali, Malika Loukiadis, Estelle Fach, Patrick Bruyand, Mathias Blanco, Jorge Bidet, Philippe Bonacorsi, Stéphane Emerg Infect Dis Research We describe the epidemiology, clinical features, and molecular characterization of enterohemorrhagic Escherichia coli (EHEC) infections caused by the singular hybrid pathotype O80:H2, and we examine the influence of antibiotics on Shiga toxin production. In France, during 2005–2014, a total of 54 patients were infected with EHEC O80:H2; 91% had hemolytic uremic syndrome. Two patients had invasive infections, and 2 died. All strains carried stx2 (variants stx2a, 2c, or 2d); the rare intimin gene (eae-ξ); and at least 4 genes characteristic of pS88, a plasmid associated with extraintestinal virulence. Similar strains were found in Spain. All isolates belonged to the same clonal group. At subinhibitory concentrations, azithromycin decreased Shiga toxin production significantly, ciprofloxacin increased it substantially, and ceftriaxone had no major effect. Antibiotic combinations that included azithromycin also were tested. EHEC O80:H2, which can induce hemolytic uremic syndrome complicated by bacteremia, is emerging in France. However, azithromycin might effectively combat these infections. Centers for Disease Control and Prevention 2016-09 /pmc/articles/PMC4994344/ /pubmed/27533474 http://dx.doi.org/10.3201/eid2209.160304 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Research Soysal, Nurcan Mariani-Kurkdjian, Patricia Smail, Yasmine Liguori, Sandrine Gouali, Malika Loukiadis, Estelle Fach, Patrick Bruyand, Mathias Blanco, Jorge Bidet, Philippe Bonacorsi, Stéphane Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge |
title | Enterohemorrhagic Escherichia coli Hybrid Pathotype
O80:H2 as a New Therapeutic Challenge |
title_full | Enterohemorrhagic Escherichia coli Hybrid Pathotype
O80:H2 as a New Therapeutic Challenge |
title_fullStr | Enterohemorrhagic Escherichia coli Hybrid Pathotype
O80:H2 as a New Therapeutic Challenge |
title_full_unstemmed | Enterohemorrhagic Escherichia coli Hybrid Pathotype
O80:H2 as a New Therapeutic Challenge |
title_short | Enterohemorrhagic Escherichia coli Hybrid Pathotype
O80:H2 as a New Therapeutic Challenge |
title_sort | enterohemorrhagic escherichia coli hybrid pathotype
o80:h2 as a new therapeutic challenge |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994344/ https://www.ncbi.nlm.nih.gov/pubmed/27533474 http://dx.doi.org/10.3201/eid2209.160304 |
work_keys_str_mv | AT soysalnurcan enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge AT marianikurkdjianpatricia enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge AT smailyasmine enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge AT liguorisandrine enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge AT goualimalika enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge AT loukiadisestelle enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge AT fachpatrick enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge AT bruyandmathias enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge AT blancojorge enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge AT bidetphilippe enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge AT bonacorsistephane enterohemorrhagicescherichiacolihybridpathotypeo80h2asanewtherapeuticchallenge |